Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17008118 | 0.85 | GRM6 (0.40) | CYP2C9CYP2C19NPSR1GRM6ALDH1A1 | |
| SCHEMBL38658851 | 0.85 | GRM6 (0.40) | CYP2C9CYP2C19NPSR1GRM6ALDH1A1 | |
| SCHEMBL25390526 | 0.80 | GRM6 (0.37) | CYP2C9CYP2C19NPSR1GRM6CISD2 | |
| SCHEMBL27809721 | 0.80 | MAPT (0.37) | CYP2C9CYP2C19NPSR1GRM6ALDH1A1 | |
| SCHEMBL30562641 | 0.80 | GRM6 (0.37) | CYP2C9CYP2C19NPSR1GRM6CISD2 | |
| SCHEMBL19023262 | 0.79 | NPSR1 (0.41) | NPSR1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL28569434 | 0.78 | HSP90AA1 (0.39) | CYP2C9CYP2C19NPSR1GRM6CNR1 | |
| SCHEMBL5712646 | 0.76 | GRM6 (0.44) | CYP2C9CYP2C19NPSR1GRM6CISD2 | |
| SCHEMBL16150656 | 0.76 | ALDH1A1 (0.46) | CYP2C9CYP2C19NPSR1GRM6CNR1 | |
| SCHEMBL1051651 | 0.75 | ALDH1A1 (0.38) | CYP2C9CYP2C19NPSR1GRM6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409922-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, MAVS, TYMP | CYP2C9 2101/4885CYP2C19 1124/4885NPSR1 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.